Review

An update on palliative therapy in advanced prostate cancer
  • Kaan Özdedeli
  • Uğur Kuyumcuoğlu
Bull Urooncol 2014; 13: 8-14
Are there any treatment option for metastatic prostate cancer refractory to docetaksel?
  • Yaşar Bedük
Bull Urooncol 2011; 10: 85-89
New treatment options for the castration resistant prostate cancer targeting the androgen synthesis and androgen receptor
  • Yavuz Selim Süral
  • Çağ Çal
Bull Urooncol 2013; 12: 106-110
New treatment options in castration resistant prostate cancer: enzalutamide and abiraterone acetate
  • Bülent Akdoğan
Bull Urooncol 2013; 12: 111-114
New treatment options for the castration resistant prostate cancer: Cabazitaxel and Spileucel-T
  • Gürbüz Görümlü
  • Erdem Göker
Bull Urooncol 2013; 12: 115-117
New treatment options in castration resistant prostate cancer: denosumab, alpharadin
  • Hakan Gemalmaz
Bull Urooncol 2013; 12: 118-122
‘Nanotechnology Applications’ in the Treatment of Prostate Cancer
  • Ali Furkan Batur
  • Kerem Gencer Kutman
  • Mustafa Suat Bolat
Bull Urooncol 2015; 14: 150-155 DOI: 10.4274/uob.375
Immunotherapy for the treatment of castration resistant prostate cancer: sipuleucel-T
  • Güven Aslan
Bull Urooncol 2012; 11: 156-158
New treatment stragies in metastatic castration resistant prostate cancer: Re-Docetaxel, Abiraterone asetate, Cabazitaxel, MDV 3100
  • Sıtkı Ün
  • Ferruh Zorlu
Bull Urooncol 2012; 11: 159-163

Original Articles

The Efficiency of Docetaxel Chemotherapy on Castration Resistant Prostate Cancer: Singe Center Experience
  • Evren Süer
  • Nurullah Hamidi
  • Mehmet İlker Gökçe
  • Sümer Baltacı
Bull Urooncol 2017; 16: 77-80 DOI: 10.4274/uob.821

About Journal

Forms

Useful Links

Applications